Bayer Schering Pharma Aktiengesellschaft – ‘6-K’ for 4/29/05 – EX-1

On:  Friday, 4/29/05, at 10:36am ET   ·   For:  4/29/05   ·   Accession #:  1124139-5-12   ·   File #:  1-16143

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Report of a Foreign Private Issuer   —   Form 6-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Facing Page                                            1      4K 
 2: EX-1        Press Release: Schering Files Lawsuit Against Barr     1      7K 
 3: EX-2        Disclaimer                                             2±     8K 
 4: EX-3        Signatures                                             1      4K 

EX-1   —   Press Release: Schering Files Lawsuit Against Barr

Schering AG files patent infringement lawsuit against Barr Laboratories,        
Inc. and Barr Pharmaceuticals, Inc.                                             

Berlin, April 29, 2005 - Schering AG, Germany (FSE: SCH, NYSE: SHR)             
announced today that it has, along with its affiliate, Berlex, Inc., filed      
a patent infringement action against Barr Laboratories, Inc. and its parent     
company Barr Pharmaceuticals, Inc. relating to Schering AG's Yasmin(R)          
(drospirenone and ethinyl estradiol) product.                                   

Yasmin(R) is the subject of an Abbreviated New Drug Application. Barr           
Laboratories, Inc. is currently seeking approval from the United States         
Food and Drug Administration to produce and market a generic version of         
Yasmin(R).                                                                      

The patent infringement lawsuit by Schering AG and Berlex, Inc. was filed       
in the United States District Court for the District of New Jersey.             

Schering AG is a research-based pharmaceutical company. Its activities are      
focused on four business areas: Gynecology&Andrology, Oncology, Diagnostic      
Imaging as well as Specialized Therapeutics for disabling diseases. As a        
global player with innovative products Schering AG aims for leading             
positions in specialized markets worldwide. With in-house R&D and supported     
by an excellent global network of external partners, Schering AG is             
securing a promising product pipeline. Using new ideas, Schering AG aims to     
make a recognized contribution to medical progress and strives to improve       
the quality of life: making medicine work.                                      

This press release has been published by Corporate Communication of             
Schering AG, Berlin, Germany.                                                   

Your contacts at Corporate Communication:                                       
Pharma Communication: Astrid Forster, T: +49-30-468 120 57,                     
astrid.forster@schering.de                                                      
Investor Relations: Peter Vogt, T: +49-30-468 128 38,                           
peter.vogt@schering.de                                                          

Your contacts in the US:                                                        

Media Relations: Rich Salem, T: +1-973-487 2371, richard_salem@berlex.com       
Media Relations: Jane Kramer, T: +1-973-487 2246, jane_kramer@berlex.com        
Investor Relations: Joanne Marion, T: +1-973-487 2164,                          
joanne_marion@berlex.com                                                        

Find additional information at: www.schering.de/eng                             

Dates Referenced Herein

This ‘6-K’ Filing		Date		Other Filings
Filed on / For Period End:		4/29/05		None on these Dates
				List all Filings